- Home
- ALVR vs AVTX Comparison
ALVR vs AVTX Comparison
Compare ALVR & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- AVTX
- Stock Information
- Founded
- ALVR 2013
- AVTX 2011
- Country
- ALVR United States
- AVTX United States
- Employees
- ALVR N/A
- AVTX N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ALVR Health Care
- AVTX Health Care
- Exchange
- ALVR Nasdaq
- AVTX Nasdaq
- Market Cap
- ALVR 87.7M
- AVTX 90.9M
- IPO Year
- ALVR 2020
- AVTX 2015
- Fundamental
- Price
- ALVR $0.57
- AVTX $9.65
- Analyst Decision
- ALVR Sell
- AVTX Buy
- Analyst Count
- ALVR 5
- AVTX 2
- Target Price
- ALVR $1.00
- AVTX $35.00
- AVG Volume (30 Days)
- ALVR 593.0K
- AVTX 68.6K
- Earning Date
- ALVR 11-12-2024
- AVTX 11-07-2024
- Dividend Yield
- ALVR N/A
- AVTX N/A
- EPS Growth
- ALVR N/A
- AVTX N/A
- EPS
- ALVR N/A
- AVTX N/A
- Revenue
- ALVR N/A
- AVTX $820,000.00
- Revenue This Year
- ALVR N/A
- AVTX N/A
- Revenue Next Year
- ALVR N/A
- AVTX N/A
- P/E Ratio
- ALVR N/A
- AVTX N/A
- Revenue Growth
- ALVR N/A
- AVTX N/A
- 52 Week Low
- ALVR $0.52
- AVTX $3.95
- 52 Week High
- ALVR $2.49
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- ALVR 37.63
- AVTX 33.29
- Support Level
- ALVR $0.52
- AVTX $12.00
- Resistance Level
- ALVR $0.64
- AVTX $13.59
- Average True Range (ATR)
- ALVR 0.10
- AVTX 0.95
- MACD
- ALVR -0.03
- AVTX -0.49
- Stochastic Oscillator
- ALVR 10.28
- AVTX 1.25
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).